A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Gastrointestinal stromal tumors in kidney transplant recipients: Report of two cases and literature review.Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.A gist of gastrointestinal stromal tumors: A review.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Recent advances and novel agents for gastrointestinal stromal tumor (GIST)New developments in mammalian target of rapamycin inhibitors for the treatment of sarcomaSystemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approachesCurrent and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialDosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Update on imatinib for gastrointestinal stromal tumors: duration of treatment.Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Reintroduction of imatinib in GISTTargeted therapy for sarcomas.Gastrointestinal stromal tumors: morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy.Current and emerging pharmacological treatments for gastrointestinal stromal tumour.Targeted therapy in GIST: in silico modeling for prediction of resistance.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Management of gastrointestinal stromal tumors.Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.Regorafenib for treatment of advanced gastrointestinal stromal tumors.Controversies in the management of gastrointestinal stromal tumors.GIST treatment options after tyrosine kinase inhibitors.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.Emerging drugs for the treatment of gastrointestinal stromal tumour.
P2860
Q26799387-8B152740-8522-4E46-9704-7FB59546B0B0Q28391684-DE5D73E5-6AA8-459C-A3F9-73B2B230B983Q30248777-DC74A447-5058-40E9-85F8-F201EF3ABD10Q33810494-05B9C5C6-DCBB-4846-9A7C-88997791439EQ34499075-32B111E9-C8C1-4137-AE9A-B8C249F642BEQ34654203-23D1D635-DB0F-40AF-B09E-A996617047DAQ34957090-5C0EBC77-9148-4BC1-A63F-09AD8915DB62Q36118178-1D280FBE-C432-44CB-BE74-8515457A8BBDQ36144084-7FA34AA7-7D9F-4EE6-8176-ACA9759D700CQ36144210-EB674BF6-9288-454D-A473-359428B177ABQ36180074-B0F29CD6-06B5-47B6-B201-2E34A81D3EAFQ36561734-2FF838BB-ACA6-4DA0-AFA2-7C92A7621698Q36910431-DB4E9306-1E4A-4E9D-BA89-9A0C9BEFB040Q36998239-F5EC4D76-4D74-4E38-AF38-F4666253D092Q37075052-452A1499-407C-4CCB-AD58-BB012E335796Q37131708-C87D45F6-BB98-4B3E-80E3-E2BF30C6744FQ37220191-AAAED371-79B8-4B27-BB5B-E2D60B19133FQ37301364-3A3C0BD1-705E-482A-A7A0-C00927D81C19Q37655450-CA4FB487-15F4-4C9D-BF05-6AA85695CFA4Q37833541-BC3CB68E-4B6D-4703-8B44-7FF181749D6BQ37841551-706089EF-E3AB-4D56-A9DC-D293204BB085Q37848666-0D2B7EC4-690B-4444-8E7C-690AAF4A75B0Q37850810-501DEDBE-A977-4D49-A59B-18F0B4FE6575Q37954207-8FBD254D-FB8C-4FCF-B3B2-DAC52CD756CEQ38081983-60850EB4-EF79-45B0-BF7C-0AD2F32A0DBAQ38100719-78BD7CBF-25B4-49A6-A7D4-0071CA6B9969Q38112821-AE961748-13D2-4FAC-A84A-72E696368B3AQ38120079-30AD9B23-A39F-444C-B191-EB08F48D90FEQ38131047-2EA9A9B0-1A4A-4E2B-8053-922A86DC741BQ38176966-56BEB35E-8E17-4800-B1F6-1F40B569F922Q38199797-69739225-3854-4C63-846C-186D04F9D4A1Q38222205-26BECA48-ABB5-4290-8C8D-560B8EDCD800Q38268165-1D237AD4-3C41-4999-ADF7-8ED559F74EB7Q38527941-03A59252-FA45-40F1-B38F-12E1323F8ED2Q38714062-3F12B432-2C67-455F-9FD3-3C89DA978AA0Q38925022-30EF4E23-5E6C-4836-860B-AF52F1981A55Q39288497-CEFFCEF6-A04F-4102-9C12-FBCA05332CF6Q41694334-FFEB6E5D-4999-49FE-BB77-D6EB2F2EEBE7Q45743838-6F18E479-F7C5-4FDC-9ECD-C52040B69112Q47355982-E32831EC-DFF8-40FD-A983-D090904647FF
P2860
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A phase I-II study of everolim ...... strointestinal stromal tumors.
@en
A phase I-II study of everolimus
@nl
type
label
A phase I-II study of everolim ...... strointestinal stromal tumors.
@en
A phase I-II study of everolimus
@nl
prefLabel
A phase I-II study of everolim ...... strointestinal stromal tumors.
@en
A phase I-II study of everolimus
@nl
P2093
P2860
P356
P1433
P1476
A phase I-II study of everolim ...... strointestinal stromal tumors.
@en
P2093
G D Demetri
I Ray-Coquard
J A Morgan
N Hollaender
P Reichardt
P Schöffski
P2860
P304
P356
10.1093/ANNONC/MDQ076
P577
2010-05-27T00:00:00Z